Immunotherapy with the trifunctional anti‐CD20 x anti‐CD3 antibody FBTA05 (Lymphomun) in paediatric high‐risk patients with recurrent CD20‐positive B cell malignancies

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|1|90-102

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.1, 2015-04, pp. : 90-102

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 701-710

John Wiley & Sons Inc

Access to resources Recommend Favorite

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

By Dillman R.  

Clinical and Experimental Medicine, Vol. 6, Iss. 1, 2006-03 ,pp. : 1-12

Springer Publishing Company

Access to resources Recommend Favorite

Dual B Cell Immunotherapy Is Superior to Individual Anti‐CD20 Depletion or BAFF Blockade in Murine Models of Spontaneous or Accelerated Lupus

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 1, 2015-01 ,pp. : 215-224

John Wiley & Sons Inc

Access to resources Recommend Favorite

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

By  

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-10 ,pp. : 194-202

Karger

Access to resources Recommend Favorite

Rituximab (Anti-CD20 Monoclonal Antibody) Administration in a Young Patient with Resistant B-Prolymphocytic Leukemia

By  

Acta Haematologica, Vol. 102, Iss. 2, 1999-10 ,pp. : 94-98

Karger

Access to resources Recommend Favorite